Literature DB >> 9228071

Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway.

D Nair1, R P Misra, J D Sallis, H S Cheung.   

Abstract

Calcium deposition diseases caused by calcium pyrophosphate dihydrate (CPPD) and basic calcium phosphate (BCP) crystals are a significant source of morbidity in the elderly. We have shown previously that both types of crystals can induce mitogenesis, as well as metalloproteinase synthesis and secretion by fibroblasts and chondrocytes. These responses may promote degradation of articular tissues. We have also shown previously that both CPPD and BCP crystals activate expression of the c-fos and c-jun proto-oncogenes. Phosphocitrate (PC) can specifically block mitogenesis and proto-oncogene expression induced by either BCP or CPPD crystals in 3T3 cells and human fibroblasts, suggesting that PC may be an effective therapy for calcium deposition diseases. To understand how PC inhibits BCP and CPPD-mediated cellular effects, we have investigated the mechanism by which BCP and CPPD transduce signals to the nucleus. Here we demonstrate that BCP and CPPD crystals activate a protein kinase signal transduction pathway involving p42 and p44 mitogen-activated protein (MAP) kinases (ERK 2 and ERK 1). BCP and CPPD also cause phosphorylation of a nuclear transcription factor, cyclic AMP response element-binding protein (CREB), on serine 133, a residue essential for CREB's ability to transactivate. Treatment of cells with PC at concentrations of 10(-3) to 10(-5) M blocked both the activation of p42/p44 MAP kinases, and CREB serine 133 phosphorylation, in a dose-dependent fashion. At 10(-3) M, a PC analogue, n-sulfo-2-aminotricarballylate and citrate also modulate this signal transduction pathway. Inhibition by PC is specific for BCP- and CPPD-mediated signaling, since all three compounds had no effect on serum-induced p42/P44 or interleukin-1beta induced p38 MAP kinase activities. Treatment of cells with an inhibitor of MEK1, an upstream activator of MAPKs, significantly inhibited crystal-induced cell proliferation, suggesting that the MAPK pathway is a significant mediator of crystal-induced signals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228071     DOI: 10.1074/jbc.272.30.18920

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  The role of crystals in articular tissue degeneration.

Authors:  H S Cheung
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

Review 2.  Familial and clinical aspects of calcium pyrophosphate deposition disease.

Authors:  A J Reginato; E Tamesis; P Netter
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

Review 3.  Phosphate sensing.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Chronic Kidney Dis       Date:  2011-03       Impact factor: 3.620

4.  PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification.

Authors:  F Rutsch; S Vaingankar; K Johnson; I Goldfine; B Maddux; P Schauerte; H Kalhoff; K Sano; W A Boisvert; A Superti-Furga; R Terkeltaub
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 5.  Calcium-Containing Crystals and Osteoarthritis: an Unhealthy Alliance.

Authors:  Richard Conway; Geraldine M McCarthy
Journal:  Curr Rheumatol Rep       Date:  2018-03-08       Impact factor: 4.592

Review 6.  Phosphocitrate as a potential therapeutic strategy for crystal deposition disease.

Authors:  H S Cheung
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.592

7.  Basic calcium phosphate crystals activate c-fos expression through a Ras/ERK dependent signaling mechanism.

Authors:  Michael L Major; Herman S Cheung; Ravi P Misra
Journal:  Biochem Biophys Res Commun       Date:  2007-02-07       Impact factor: 3.575

8.  Point: Hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis.

Authors:  Geraldine M McCarthy; Herman S Cheung
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 9.  Calcium pyrophosphate dihydrate and basic calcium phosphate crystal-induced arthropathies: update on pathogenesis, clinical features, and therapy.

Authors:  Hang-Korng Ea; Frédéric Lioté
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

Review 10.  Hydroxyapatite deposition disease of the joint.

Authors:  Eamonn S Molloy; Geraldine M McCarthy
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.